Table 5.

Clinical Outcomes for Entire Study Cohort by Overall Serum-Associated Antibiotic Tolerance (SAT) Status and SAT Pharmacologic Phenotype

Outcome	SAT-Negative (n = 15)	SAT-Positive (n = 29)	P Value	Minocycline SAT-Positive (n = 23)	P Value	Tobramycin SAT-Positive (n = 13)	P Value
Duration with fever, median (IQR), d	1.0 (0.0, 1.0)	0.0 (0.0, 1.0)	.16	0.0 (0.0, 1.0)	.22	0.0 (0.0, 1.0)	.45
Duration in pediatric intensive care unit, median (IQR), d	1.0 (0.0, 5.0)	0.0 (0.0, 7.0)	.87	0.0 (0.0, 10.0)	.90	0.0 (0.0, 11.0)	.87
Hospital length of stay, median (IQR), d	7.0 (5.0, 14.0)	9.0 (6.0, 18.0)	.53	9.0 (6.0, 18.0)	.52	11.0 (7.0, 20.0)	.28
Duration of antibiotics, median (IQR), d	5.0 (5.0, 8.0)	8.0 (5.0, 10.0)	.23	8.0 (3.0, 11.0)	.25	8.0 (6.0, 10.0)	.14
Duration of oxygen therapy (>home requirement), median (IQR), d	5.0 (0.0, 11.0)	4.0 (0.0, 8.0)	.66	5.0 (0.0, 9.0)	.80	3.0 (0.0, 8.0)	.72
Mortality, n (%)	0 (0.0)	2 (6.9)	.54	2 (8.7)	.51	2 (15.4)	.21

Abbreviation: IQR, interquartile range; SAT, serum-associated antibiotic tolerance.